1.43
price down icon23.94%   -0.45
after-market After Hours: 1.47 0.04 +2.80%
loading
Vyne Therapeutics Inc stock is traded at $1.43, with a volume of 1.66M. It is down -23.94% in the last 24 hours and down -17.82% over the past month. VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$1.88
Open:
$1.46
24h Volume:
1.66M
Relative Volume:
11.43
Market Cap:
$27.23M
Revenue:
$486.00K
Net Income/Loss:
$-28.43M
P/E Ratio:
-0.5073
EPS:
-2.8189
Net Cash Flow:
$-26.75M
1W Performance:
-22.70%
1M Performance:
-17.82%
6M Performance:
-46.44%
1Y Performance:
-42.11%
1-Day Range:
Value
$1.28
$1.50
1-Week Range:
Value
$1.28
$1.9933
52-Week Range:
Value
$1.28
$4.30

Vyne Therapeutics Inc Stock (VYNE) Company Profile

Name
Name
Vyne Therapeutics Inc
Name
Phone
800-775-7936
Name
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Name
Employee
13
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
VYNE's Discussions on Twitter

Compare VYNE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VYNE
Vyne Therapeutics Inc
1.43 27.23M 486.00K -28.43M -26.75M -2.8189
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-18-24 Initiated BTIG Research Buy
Dec-06-21 Resumed H.C. Wainwright Buy

Vyne Therapeutics Inc Stock (VYNE) Latest News

pulisher
Apr 25, 2025

VYNE stock touches 52-week low at $1.38 amid market challenges - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

After A -27.64% Drop In Share Price, Is VYNE Therapeutics Inc (NASDAQ:VYNE) A Better Trade Than Others? - Marketing Sentinel

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics Inc (VYNE) Stock: A Year of Highs and Lows in the Market - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE’s earnings forecast for the current quarter - uspostnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - Benzinga

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down. - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

FDA Places Clinical Hold on VYNE’s VYN202 Phase 1b Trial for Plaque Psoriasis - Dermatology Times

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics (VYNE) Target Price Cut Following FDA Clinical - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics (VYNE) Faces FDA Clinical Hold on Psoriasis Dr - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

With 36.89% Distance From Low, Could Vs Media Holdings Ltd (NASDAQ:VSME) Post Further Gains? - Marketing Sentinel

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Says FDA Halted Psoriasis Drug Trial After Signs of Toxicity Found; Shares Down Pre-Bell - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics Provides Update on VYN202 Program - The Manila Times

Apr 25, 2025
pulisher
Apr 24, 2025

VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 1.1% – Here’s What Happened - Defense World

Apr 24, 2025
pulisher
Apr 18, 2025

Is VYNE Therapeutics Inc (NASDAQ: VYNE) A Suitable Stock For New Investors Today? - Stocksregister

Apr 18, 2025
pulisher
Apr 08, 2025

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - Yahoo Finance

Apr 08, 2025
pulisher
Apr 04, 2025

Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail

Apr 04, 2025
pulisher
Apr 02, 2025

VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update - Defense World

Apr 02, 2025
pulisher
Mar 21, 2025

Vyne therapeutics director Patrick Lepore buys $43,800 in stock - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Invesco Canada announces cash distributions for its ETFs - The Globe and Mail

Mar 21, 2025
pulisher
Mar 20, 2025

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

VYNE Therapeutics Showcases Breakthrough Autoimmune Disease Treatments at Major Conference - StockTitan

Mar 20, 2025
pulisher
Mar 11, 2025

Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 11, 2025
pulisher
Mar 08, 2025

VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

VYNE Therapeutics Reports Progress in Clinical Trials - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Est - GuruFocus.com

Mar 06, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Inc. (VYNE) reports earnings - Quartz

Mar 06, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga

Mar 06, 2025
pulisher
Mar 06, 2025

Vyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times

Mar 06, 2025
pulisher
Feb 27, 2025

VYNE Therapeutics (VYNE) Projected to Post Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 21, 2025

HC Wainwright Reiterates “Buy” Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

VYNE Therapeutics to Participate in March Investor Conferences - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

Can VYNE Therapeutics' March Investor Conferences Reveal New Strategic Directions? - StockTitan

Feb 20, 2025
pulisher
Feb 19, 2025

VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

VYNE Therapeutics Initiates Phase 1b Trial Of VYN202 For Plaque Psoriasis Treatment - Nasdaq

Feb 19, 2025
pulisher
Feb 19, 2025

Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - The Manila Times

Feb 19, 2025
pulisher
Feb 19, 2025

Can This New Psoriasis Drug Revolutionize Treatment? VYNE's Latest Clinical Trial Reveals Key Details - StockTitan

Feb 19, 2025
pulisher
Feb 19, 2025

VYNE begins trial for new psoriasis treatment - Investing.com

Feb 19, 2025
pulisher
Jan 20, 2025

VYNE Therapeutics Updates Corporate Presentation and Pipeline Progress - Defense World

Jan 20, 2025
pulisher
Jan 17, 2025

Vyne therapeutics director Patrick Lepore buys $43,800 in stock By Investing.com - Investing.com Australia

Jan 17, 2025
pulisher
Jan 17, 2025

Insider Buying: Patrick Lepore Acquires 15,000 Shares of VYNE Th - GuruFocus

Jan 17, 2025
pulisher
Jan 14, 2025

VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail

Jan 13, 2025
pulisher
Jan 10, 2025

Financial Analysis: Skye Bioscience (NASDAQ:SKYE) vs. VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Jan 10, 2025
pulisher
Jan 07, 2025

VYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligo - Yahoo Finance

Jan 07, 2025
pulisher
Jan 07, 2025

VYNE Therapeutics’ (VYNE) Buy Rating Reaffirmed at HC Wainwright - Defense World

Jan 07, 2025
pulisher
Jan 06, 2025

Forecasting The Future: 4 Analyst Projections For VYNE Therapeutics - Benzinga

Jan 06, 2025
pulisher
Jan 06, 2025

VYNE Therapeutics' (VYNE) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Jan 06, 2025

Vyne Therapeutics Inc Stock (VYNE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):